Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7771950 versus tucatinib with trastuzumab + capecitabine in previously treated HER2-positive advanced breast cancer
MOH_2026-05-19_015830Phase 3Recruiting
- Sponsor
- Roche
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of RO7771950, tucatinib, trastuzumab and capecitabine in breast cancer (5 arms), sponsored by Roche. Primary endpoints: Dose selection for RO7771950 for Phase 2 and Efficacy of RO7771950 + trastuzumab + capecitabine versus tucatinib + trastuzumab + capecitabine. Started Mar 2026; status: recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on MOH_2026-05-19_015830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-05-19_015830.